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ABSTRACT  
  
 
The natural decline in estrogen that occurs in women during menopause causes 
significant discomfort and decrease in quality of life for women. Botanical supplements contain 
multiple bioactive components, some of which have been identified to be phytoestrogenic and 
are used to remedy menopausal symptoms.  However, due to their ability to mimic estrogen, the 
phytoestrogenic components contained in these botanical supplements may play a role in the 
progression of breast cancer. The majority of botanicals lack established data on safety and 
efficacy. They also present the likelihood for interactions to occur, such as with the high fat diet 
that is consumed in many Western countries.  
Two such botanicals, licorice root and epimedium, which are used to alleviate 
menopausal symptoms, were studied for their impact on the progression of metastatic breast 
cancer in an animal model. In the licorice study, mice were supplemented with licorice root 
powder, extract or isoliquirtigenin for 2 weeks before and 3 weeks after cell injection. The 
effects of supplementation with the same licorice compounds alongside a high-fat diet were also 
explored. Mice fed licorice root powder and isoliquiritigenin were found to have a reduction in 
lung metastasis compared to control. In the high fat group, no changes in lung metastasis were 
found in animals supplemented with licorice root compounds compared with control. Although 
mild hepatocellular hypertrophy was observed in the liver of mice fed licorice root compounds, 
no significant adverse effects were found. In the epimedium study, mice were fed epimedium 
powder, extract or icariin for 12 weeks before and 4 weeks after cell injection. A second cohort 
also received the same epimedium treatments alongside a high fat diet. Supplementation with 
epimedium compounds had no effect on lung metastasis in the control groups, while only 
epimedium powder was found to decrease lung metastasis in the high fat cohorts. No adverse
 iii 
effects due to epimedium supplementation were found. In this animal model, supplementation 
with licorice root or epimedium compounds did not have a promoting effect on breast cancer 
metastasis. Both licorice and epimedium possess properties that could be advantageous toward 
the development of novel pharmacological treatments. However, the safety of licorice root or 
epimedium supplement use remains uncertain due to the possibility of interaction with dietary 
components and should be approached with caution. 
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CHAPTER 1: INTRODUCTION 
Breast cancer (BC) encompasses the largest percentage of cancers in women worldwide 
and is the most significant contributor to cancer related mortality. In the U.S, breast cancer (BC) 
affects 12% of the female population and is the second leader of death in women. Though breast 
cancer mortality rates have gone down in the last ten years, there are still 40,000 American 
deaths due to breast cancer each year. Mortality incidence dramatically increases once a woman 
advances to late stage breast cancer, which involves metastasis to distant tissues such as lymph, 
lung and bone. Bone metastasis is a source of chronic pain for patients and has no standardized 
treatment. Micrometastasis, tiny undetectable tumors that are precursor to secondary tumors, 
were found in the bone at the time of diagnosis in approximately 30% of patients. The presence 
of bone micrometastasis were an indication for poor diagnosis and lower survival rate
1
. 
Modifiable lifestyle factors such as diet may factor into the development of detectable tumors in 
the bone from micrometastasis. Botanicals taken by the postmenopausal population pose a risk 
due to their phytoestrogen content. The high-fat diet that is consumed by American women has 
also been shown to increase the risk for breast disease.   
Menopause, which is marked by a reduction in ovarian function and a decline in the 
production of estrogens, is a natural process of aging in women. During menopause, symptoms 
such as weight gain, hot flashes, night sweats, mood changes, and diminished sexual function
2
 
may appear as a result. In order to alleviate these symptoms, Hormone Replacement Therapy 
(HRT), synthetic estrogens in the form of a pill, skin patch, or topical application was commonly 
prescribed. Although HRT is effective for menopausal symptoms, use has declined since the 
emergence of evidence linking HRT with an increased risk of breast cancer, as well as other 
possible health risks
3,4
. Consequently, postmenopausal women have sought alternatives in order 
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to relieve their symptoms. Botanical supplements are a popular form of alternative therapy 
thought to improve menopausal symptoms through their phytoestrogenic properties
5
. A study at 
the University of Illinois at Chicago clinics reported that 79% of peri- and postmenopausal 
women were using botanical dietary supplements
6
. Botanicals are perceived to be safe for 
consumption because they provide a natural source of phytoestrogens. However, the safety and 
efficacy of ingesting botanical phytoestrogens is undetermined.  
The phytoestrogen genistein contained in soy seems to play a protective effect when 
consumed as a regular part of the diet
7
, but may exacerbate the growth of breast tumors when 
consumed as a supplement in later life
8
.  The phytoestrogens found in botanicals structurally 
resemble estrogen and therefore have the capacity to bind to estrogen receptors (ER). Estrogens 
act as ligands to bind to estrogen receptor (ER) to modulate gene responses. While estrogens 
play a crucial role in the female body by regulating menstruation, sexual development, sexual 
reproduction, and metabolism
9
, binding to either of the estrogen receptors, ERα or ERβ, can 
contribute to the progression of breast cancer. ERα is thought to modulate most of the pro-
oncogenic action while ERβ plays a moderating role9,10. Botanicals have a higher affinity toward 
ERβ than ERα, but since the ERs share a large homology, possess the potential to turn on or off 
genes that regulate cancer growth
11
.  
The main types of estrogen in the body are 17β-estradiol (E2) as well as estrone (E1) and 
estriol (E3). In premenopausual women, E1 and E2 are secreted by the ovaries throughout the 
menstrual cycle, with some coming from the adipose tissue or adrenal glands, while E3 is 
secreted by the placenta during pregnancy
9,10
. In postmenopausal women, estrogen synthesis in 
the ovaries is low, and the primary source of estrogen is synthesized by aromatase, which lies in 
the adipose tissue, as well as in ovaries, placenta, bone, skin and brain
12,13
. Therefore, for 
 
 
3 
 
 
postmenopausal women who are obese, estrogen synthesis in the adipose becomes more 
significant. Obesity is a growing problem in the U.S and is an important contributor to survival 
outcomes in breast cancer patients. Patients who were classified as overweight or obese prior to 
diagnosis had a higher risk of mortality due to breast cancer
14
. When compared with normal 
individuals, postmenopausal women who were overweight or obese and had been diagnosed and 
treated for breast cancer were shown to have a greater incidence of recurrence or disease 
progression
15
. High fat diets that are consumed by the American population are often associated 
with the development of obesity.  
Studies regarding the role of high dietary fat consumption and breast cancer are 
inconsistent, but some suggest a positive correlation. Higher incidence of invasive breast cancer 
was found in women with higher intakes of total fat and saturated fat when compared with 
women with the lowest intakes of fat
16,17
. Women consuming greater amounts of saturated fat, 
monounsaturated fat, and total fat before breast cancer diagnosis were also reported to have a 
higher risk of death
18
. A diet high in dietary fat, along with the use of botanical supplements for 
menopausal symptoms, may have unintended consequences for those with or at high risk for 
developing breast cancer. The progression of breast cancer to metastatic breast cancer in the 
bone can be life-debilitating and accounts for a large portion of deaths. Botanicals exhibit 
estrogenic properties that may protect women from breast cancer metastasis or may stimulate the 
growth of developing tumors. The interactions exerted by a diet high in fat can complicate the 
situation. The effects of consuming botanical supplements and a high fat diet in combination or 
alone could instigate the growth of breast tumors and metastasis, and there is a need to delineate 
those outcomes.  
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My research project focuses on two botanicals, licorice root and epimedium, which are 
available on the retail market and consumed by women for menopausal symptoms. Although a 
number of studies have shown the effects of these botanicals on breast cancer, there is limited 
knowledge on their effects on breast cancer metastasis. Many animal studies have shown a 
relationship between high-fat diets and increased breast cancer incidence. These studies are 
conducted using a standard rodent “chow” diet, which is a relatively healthy diet with a low fat 
content. The dietary fat content in these studies do not account for the higher amounts of fat 
(approximately 33% of total kcal according to the CDC) that an average American woman would 
be consuming. The combination of a high-fat diet with botanical supplementation has not been 
investigated in animals or in humans. Furthermore, no studies have taken into account the 
possibility of an interaction between botanical supplementation and the level of fat consumed in 
a breast cancer animal model. In order to make the study as relevant to our target population as 
possible, we give animals levels of botanical and high levels of fat that are achievable in 
humans.   Using an animal mouse model will help us characterize possible clinical outcomes in a 
breast cancer patient.  Using a cell line that spontaneously and preferentially metastasizes to the 
lung when injected into the bone of the animal allows us to measure the degree of metastasis by 
counting the number of metastatic lung nodules.  As of such, no studies have utilized an in vivo 
mouse bone model to mimic the metastasis from bone to lung to investigate the effects of 
botanicals. In addition, the potency of whole botanical (in dried powder form), botanical extract, 
and bioactive component in a breast cancer metastasis model will be compared.    
The long-term goal of this project was to assess the potential health risk and/or benefit of 
botanical consumption in women who are at risk for breast cancer by examining the effect of 
botanical supplementation of licorice root and epimedium on BC growth and metastasis. The 
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objective of these studies were to determine how botanical consumption of licorice and 
epimedium affects breast cancer metastasis in a preclinical breast cancer metastasis model 
representative of a woman who is at risk for breast cancer.  
The hypothesis for these studies are that licorice root and epimedium compounds would 
reduce the metastasis of 4T1 murine breast cancer from bone to lung in a preclinical OVX 
Balb/C model and that a high fat diet (HF) compared to control diet (C) would negate or alter 
those effects. 
The specific aims for this project are as follows: 1) To investigate the effects of licorice 
and epimedium, in the form of whole botanical (in dried powder form), botanical extract, and 
bioactive component on breast cancer metastasis from bone to lung in a murine model, 2) To 
determine if there is an interaction effect between licorice or epimedium with dietary fat 
This thesis is divided into five chapters. Chapter 2 goes into detail about the general and 
estrogenic properties of licorice root and epimedium, as well as their relationship to breast 
cancer. More information will also be provided on the high fat breast cancer models used in 
other animal studies. Chapter 3 will describe the findings from the licorice root study while 
Chapter 4 will narrate results and discussion from the epimedium study. Chapter 5 will further 
summarize the research findings and their implications for future work.  
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CHAPTER 2: LITERATURE REVIEW 
Estrogens and Cancer 
Estrogen is a crucial hormone that is responsible for development, maintenance and 
regulation in the female body. The main types of estrogen in the body are 17β-estradiol (E2) as 
well as estrone (E1) and estriol (E3). In premenopausual women, E1 and E2 are secreted by the 
ovaries throughout the menstrual cycle, with some coming from the adipose tissue or adrenal 
glands, while E3 is secreted by the placenta during pregnancy
1,2
. In postmenopausal women, 
estrogen synthesis in the ovaries is low, and the primary source of estrogen is synthesized by 
aromatase, which lies in the adipose tissue, as well as in ovaries, placenta, bone, skin and 
brain
3,4
. For postmenopausal women who are obese, estrogen synthesis in the adipose may be 
more significant. Excess exposure to estrogens is also associated with greater risk of breast 
cancer
5
. Multiple epidemiological studies
6,7
 as well as randomized controlled trials
8,9
 have 
supported the original findings from the Women’s Health Initiative Study that hormone 
replacement therapy (HRT) in the forms of combined estrogen/progesterone therapy as well as 
estrogen therapy alone were associated with a higher incidence of invasive breast cancer in 
current users and those who had stopped use 1-4 years before diagnosis
10
. It is postulated that 
mechanisms of estrogen on breast carcinogenesis include the metabolism of estrogen into 
genotoxic or mutagenic metabolites and the stimulation of tissue growth through estrogen 
signaling
11
. Estrogen acts by binding to estrogen receptor (ER), which is found in many tissues 
of the body, like uterus, ovary, mammary gland, prostate, lung and brain. Activated estrogen-ER 
complex causes changes in protein structure and allows interaction with coactivators or 
corepressors. The complex can regulate gene transcription by directly binding to estrogen 
response elements (ERE) located in promoters of target genes or through protein-protein 
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interactions with other transcription factors.  Alternatively, phosphorylation of ERs by activated 
kinases stimulated by growth factor receptors can also lead to activation. The activated ERs are 
also subject to post-translational modifications that can affect their activity
1,12,13
. To add to the 
complexity of estrogen signaling, the two types of estrogen receptor, ERα and ERβ, share a large 
homology (~59%) and perform opposing roles in cellular processes. In general, interactions with 
ERα are linked to proliferative effects while interactions with ERβ are linked to inhibition of 
growth. ERα expression is often increased in early breast tumors while ERβ is reduced14. The 
spacious ligand cavity of ER allows for binding of molecules with some resemblance to 
estrogen
15
.  
 
Figure 2.1. Estrogen Receptor Ligand Activation Pathways. Adapted from Heldring et al
13
. 
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Figure 2.2. Estrogen Receptor Signaling Pathways. Abbreviations: cAMP denotes cyclic AMP, 
E2 estradiol, 4-OH-E2 4-hydroxyestradiol, ER estrogen receptor, EGF epidermal growth factor, 
EGFR epidermal growth factor receptor, IGF-1 insulin-like growth factor 1, IGF-1R insulin-like 
growth factor 1 receptor, MAPK mitogen-activated protein kinase, mRNA messenger RNA, 
MPI3K phosphoinositide 3 kinase, mtProteins mitochondrial proteins, and pShc phosphorylated 
Shc protein. Dashed-line arrows indicate putative pathway. Adopted from Yager and Davidson
11
. 
 
Botanical Phytoestrogens 
As such, HRT is used to relieve symptoms such as hot flashes, night sweats, insomnia 
and others by menopausal women and women who have undergone adjuvant therapies for breast 
cancer. With the mounting evidence that the risks of using of HRT outweigh its benefits, women 
have sought alternative forms of relief through natural botanical supplements, which contain 
phytoestrogens. Phytoestrogens have similar structures to estrogen and tend to have low 
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affinities to ER when compared with estrogen
16
.  Botanicals also have a higher affinity toward 
ERβ than ERα 17. Studies investigating the potential benefits of phytoestrogens against the 
development of hormone-responsive cancers have yielded ambiguous results. Epidemiological 
studies have found that the rates of breast cancer in Asian countries are much lower compared to 
the Western hemisphere
18,19
, presumably due to higher intakes of soy and isoflavones
20-22
.  Other 
studies have found no relationship between the consumption of phytoestrogens such as soy and 
the risk of breast cancer
23,24
. However, breast cancer patients and survivors are not recommended 
to use botanical phytoestrogens. Due to the vast array of available phytoestrogens and the 
diversity of their actions, more research is needed to determine their safety, especially towards 
breast cancer. Two botanicals of interest, licorice root and epimedium, will be discussed further 
in the following portions of this review. 
Figure 2.3. Chemical structure of isoliquiritigenin, a bioactive estrogenic component of licorice 
root and chemical structure of icariin, a bioactive estrogenic component of epimedium, in the 
orientation that is most like estradiol.  
 
Estradiol   Isoliquiritigenin       Icariin 
Licorice Root Historical and Commercial Use 
Licorice root (genus name Glycyrrhiza) has a long history of use in Western and Eastern 
cultures. Licorice (LR) has been used as a remedy for ailments such as stomach ulcers, 
bronchitis, sore throat and hepatitis, as well as a sweetening and flavoring agent. Today, it is 
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mainly grown in Greece, Turkey and Asia, is still used in folk medicine and Chinese medicine
25
, 
and is a popular ingredient for tobacco and confectionary products. Commercial preparation of 
licorice products involves the drying of the root, the mashing and boiling of the root into pulp, 
and removal of solids to form a paste, which can then be vaccuum dried into blocks or dried to 
powder, depending on the application
26
. The primary flavor compound found in licorice root is 
glycyrrhizin, which is also an active compound. Large amounts and long-term use have been 
known to cause edema, hypertension and hypokalemia
27
. Licorice root and its constituents have 
been reported to be antioxidative, anti-inflammatory, antiviral/antimicrobial, and 
anticarcinogenic. Licorice root and its derivatives are considered GRAS by the U.S Food and 
Drug Administration. The three main species of licorice grown in China are Glycyrrhiza glabra, 
Glycyrrhiza uralensis, and Glycyrrhiza inflata. Licorice root contains multiple bioactive 
compounds comprising saponins, flavonoids, isoflavones, coumarins, and stilbenoids
28
. Of these, 
the triterpenoid saponin glycyrrhizin (consisting of potassium and calcium salts of glycyrrhizic 
or glycyrrhizinic acid, and glycyrrhetinic acid) is considered to be present in highest amounts 
and contributes to the sweetness of licorice root.  Other widely researched components include 
the flavonoids liquiritigenin, isoliquiritigenin, and licochalcones, as well as the isoflavonoid 
derivatives glabridin and glabrene, all of which have been reported to have estrogenic activity
29-
31
. Glycyrrhizin has not been found to be teratogenic, genotoxic, or toxic to fetal development
32
. 
Glycyrrhizin was evaluated in 2005 at the Joint FAO/WHO Expert Committee on Food 
Additives and it was determined that a consumption of 100 mg/day would not cause adverse 
effects in most adults
26
. Licorice root and its constituents have been reported to be antioxidative, 
anti-inflammatory, antiviral/antimicrobial, and anti-carcinogenic. Overall, licorice root is widely 
used and is relatively safe for consumption. 
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Isoliquiritigenin Bioavailability and Metabolism 
Isoliquiritigenin (ILQ) is a compound of interest that is found in licorice root and is a 
precursor chalcone which forms liquiritigenin (LQ) after cyclization. Liquiritin and isoliquiritin 
are glycones of ILQ and LQ. In mice, isoliquiritigenin was detectable in plasma five minutes 
after oral administration, suggesting that it was quickly absorbed through the gastrointestinal 
tract. Tissue/plasma ratios of ILQ after were greater than unity (T/P >1) in liver, spleen, stomach, 
small intestine, large intestine, kidney, and lung, indicating high distribution per oral 
administration. Mean plasma concentrations of ILQ and LQ after iv doses of 2.5-20 mg/kg ILQ 
and oral doses of 10-100 mg/kg ILQ were not significantly different
33
. Plasma concentration-
time profiles of ILQ after venous and oral administration was similar in rats; however, LQ was 
below the detection limit 30 min after adiminstration.  It was estimated that oral absorption of 
ILQ was about 92% absolute bioavailability was about 11.8%
34
. In human liver microsomes, 
isoliquiritigenin was mainly converted to liquiritigenin upon Phase 1 metabolism, as well as six 
other metabolites (2′,4,4′,5′-tetrahydroxychalcone, sulfuretin, butein, davidigenin, trans-6,4′-
dihydroxyaurone, and cis-6,4′-dihydroxyaurone)35. Cytochrome P450 CYP 2C19 and UDP-
glucoronysyltransferase 1A were primarily responsible for the second phase of metabolism for 
ILQ. Phase 2 metabolism in human hepatocytes produced LQ and five monoglucoronides of 
ILQ, with UGT1A1 and UGT1A9 producing the most common metabolite. Some metabolites 
were formed by human intestine and kidney microsomes as well
36
.  
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Fig 2.4. Chemical Structures of Licorice Chalconoids. Adapted from Kao et al
37
.  
 
Licorice Root and Estrogenicity 
Estrogenic activity of licorice root has been established in many studies. Licorice root can 
be fractionated to licorice root extracts using various solvents: DMSO for compounds of 
differing polarities, hexane for non-polar phytochemicals, ethyl acetate and methanol for 
compounds with intermediate polarity, and hot water for polar phytochemicals. Contrasting 
effects on cell growth were seen using extracts made from different solvents. DMSO and ethyl 
acetate extracts showed biphasic effects on MCF-7 growth, where low concentrations promoted 
ER-dependent growth and high concentrations inhibited growth independent of ER. Hexane 
extracts had no effect on growth, while methanol and water extracts promoted ER-independent 
growth
38
.  Fractionated ethyl acetate extracts of licorice root all exhibited estrogenic responses 
that were ER-mediated due to an ablation of activity in the presence of an ER-antagonist and a 
lack of activity in cells that did not contain ER. Glabrene-rich fractions preferentially bound to 
ERalpha to activate, whereas glabridin behaved as an ERα antagonist39. It has been suggested 
that the large range of compounds found in licorice root may exert both estrogenic and ant-
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estrogenic effects. The main phenolic compounds found in licorice root are liquiritin and its 
chalcone derivative isoliquiritin, as well as liquiritigenin and its chalcone derivative 
isoliquiritigenin
40. ILQ can bind to ERα and ERβ of various cell types and displayed a biphasic 
effect on proliferation of MCF-7 cells
41
. Liquiritigenin, the metabolite of isoliquiritigenin, has 
very low relative binding affinity to either of the ER’s when compared with genistein, but 
preferentially binds and activates ERβ42. Although liquiritigenin has only a 20-fold greater 
binding affinity to ERβ over ERα, it selectively recruits coactivators to ERβ, making it a more 
potent and effective ligand of ERβ43. In addition to the agonistic actions of isoliquiritigenin and 
liquiritgenin on ER, four other compounds isolated from licorice root (calycosin, 
methoxychalcone, vestitol, and glycycoumarin) were identified as ER agonists and three other 
compounds (glabridin, glyasperin C, and glicocoricone) were identified as ER antagonists.
44
 
These findings suggest that collectively, components of licorice root can act as selective estrogen 
receptor modulators (SERM)s, which may explain the differences in activity reported from 
previous studies.  
Licorice Root and Cancer 
Very few studies have looked at the pharmacological properties of licorice root powder 
alone. This may be attributed to the potential toxicity of glycyrrhizin present in whole licorice 
root, while in Chinese medicine, licorice root is most often used in combination with other herbs. 
Most studies have investigated the activities of licorice root extract or isolated compounds from 
licorice root.   Licorice root extracts were shown to inhibit proliferation of colon cancer cells
45
, 
decrease the metastatic potential of prostate cancer cells
46
, and induced apoptosis of breast 
cancer cells
47
. However, it should be noted that the triterpene saponin content of licorice roots 
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differ depending on the species used
48
 and cytotoxicity of licorice roots can vary based on 
geographical area and timing of harvest
49
.  
Isoliquiritigenin is present in all Glycyrrhiza species and has been widely studied for 
cancer prevention. ILQ was able to suppress tumor growth of colon, prostate, lung, and breast 
cancer cells. ILQ was proposed to decrease cyclooxygenase (COX) and inducible nitric oxide 
synthase (iNOS), two factors that are considered relevant to colon cancer. Protein levels of COX-
2 and iNOS were decreased in macrophages with ILQ treatment. In rat colons, ILQ inhibited 
formation of total and large carcinogen-induced pre-neoplastic abberant crypt foci (ACF)
50
. In 
adenoid cystic carcenoma cells, isoliquirtigenin caused apoptosis. Membrane-mediated apoptosis 
is regulated by proteins of the Bcl-2 family. Bcl-2 works to protect the mitochondrial outer 
membrane while Bax promotes the release of pro-apoptotic facters such as cytochrome c and 
Smac/Diablo.  Isoliquiritigenin was found to induce apoptosis of both rat and human prostate 
cancer cells, which was correlated with increased levels of Bax protein, as well as cytochrome c 
and Smac/Diablo. ILQ was not toxic to intestinal epithelial cells
51
. Tumors are thought to 
produce arachidonic acids, which are metabolized by COX, lipoxygenase, and cytochrome P50 
(CYP) to eicosanoids such as prostaglandin E2 (PGE2), leuokotriene B4 (LTB4). Eicosanoids can 
then promote cancer cell survival by activating phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway. It was established that ILQ decreased cell viability and induced apoptosis in breast 
cancer cells MCF-7 and MDA-MB231 by significantly lowering mRNA levels of sPLA2, COX-
2 and CYP4A1. ILQ also suppressed secretion of PGE2 and lowered Akt kinase activity, 
indicating downregulation of AA metabolic network and deactivation of PI3K/Akt pathway. 
Additionally, tumor growth MDA-MB-231 xenografts in nude mice were inhibited with 
treatment of isoliquiritigenin at 50 and 100 mg/kg IP dosages
52
.   
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Bone resorption by osteoclasts releases growth factors from bone matrix that may 
contribute to proliferation of cancer cells in the bone. Roasted licorice root extracts inhibited 
RANKL secretion but had no effect on OPG. The ethanolic extract of roasted licorice root 
reduced the viability of MDA-M231 cells in a dose-dependent manner. Treatment with licorice 
root extract by gavage (0.5, 1, or 2 mg/kg body weight) reduced tumor growth and extent of bone 
destruction in tibia of animals injected with MDA-MB231 cells.
53
 
Licorice Root and Metastasis  
The anti-metastatic effects of ILQ in prostate cancer cells were investigated. ILQ 
inhibited basal and EGF-induced migration and invasion of prostate cancer cells, as well as 
adhesion. ILQ also reduced MMP-2 and VEGF in prostate cancer cells. Binding of EGF to EGF 
receptor leads to downstream activation of several signaling molecules. ILQ was found to inhibit 
phosphorylation of Akt, JNK, and c-Jun , but not p38 MAPK or ERK1/2
54
. In lungs of mice 
injected with renal carcinoma cells, ILQ treatment significantly reduced the number of metastatic 
nodules at 2 and 10 mg/day for 10 days.
55
 Licochalcone E, another phenolic constituent of 
licorice root, reduced tumor growth with oral administration of 14 mg/kg and tumor nodules in 
lung with oral administration of 7-14 mg/kg in mice injected with 4T1 cells
56
. Proposed 
mechanisms are decreased angiogenesis through inhibition of VEGF expression due to 
accelerated degradation of upstream HIF-1α proteasome in MDA-MB-231 cells57. Further 
support of ILQ’s anti-metastatic capabilities was demonstrated with a decrease in surface lung 
tumors with ILQ treatment of 10 and 20 mg/kg BW in mice injected with MDA-MB-231 cells. 
These results were correlated with a decrease in levels of PGE2 and 20-HETE, phospho-Akt, 
MMP-2 and MMP-9 in primary tumors of animals treated with ILQ
58
. 
Epimedium Historical and Commercial Use  
 
 
18 
 
 
Epimedium, or Herba Epimedii, is a genus of 21 species of plants that are grown in Asia 
and the Mediterranean. It is also known commonly as horny goat weed, barrenwort, and yin yang 
huo. The leaves and stems of Epimedium are used as a supplement, historically as a remedy for 
kidney dysfunction, impotence, and as an aphrodisiac or stimulant. Species used for medicinal 
purposes are Epimedium sagittatum, Epimedium brevicornum, Epimedium wushanense, 
Epimedium koreanum, and Epimedium pubescens. Epimedium has been investigated for its 
abilities to treat sexual dysfunction, osteoporosis, cardiovascular disease, asthma, bronchitis, and 
sinusitis
59
. Long term use of Epimedium in Chinese medicine has been safe when consumed 
orally at around 5 g or at around 300 ml of extract daily for up to 6 months. Individuals with pre-
existing conditions such as cardiovascular disease, hypertension, muscoskeletal disorders, 
bipolar disorder, hypothyroid conditions, and respiratory disorders are recommended not to take 
Epimedium
60
. Excessive intake of epimedium can cause vomiting, dizziness, thirst and 
nosebleed
61
. 
Bioavailability and Metabolism 
Epimedium consists of many bioactive compounds and is a rich source of 
prenylflavonoids. Icariin, the principal component of Epimedium, contains a glucose and a 
rhamnose residue. Partial deglycosylation results in icariside I and icariside II, and further 
deglycosylation results in icaritin. Other isolated and studied compounds with estrogenic 
properties include ikarisoside A
62
, baohuoside I and baohuoside II
63
, breviflavone B
64
, epimedin 
B and epimedin C
65
. A mixture of icariin, icariside I, icariside II, and icaritin were contained in 
an ethanolic extract of Epimedium. All derivatives appeared in the nanomolar range after 
administration of 100, 300 and 600 mg/kg/BW of epimedium extract to rats. Although icariin 
held the highest flavonoid content in epimedium, it was quickly metabolized to icariside II by 
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first-pass deglycosylation. After digestion with glucoronidase, only icariside I, desmethylicaritin, 
and icaritin were detectable. Additionally, saturation of icaritin was observed at higher levels of 
epimedium extract administration
66
.  
Figure 2.5. Structures of icariin and its derivatives. Adapted from Wong et al 
66
. 
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Epimedium and Bone Health 
Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. 
The main players in bone maintenance are osteoblasts and osteoclasts. Osteoblasts produce 
receptor activator of NFκB ligand (RANKL), whose receptor (receptor of NFκB) is found on 
osteoclasts. Osteoblasts also secrete osteoprotogerin (OPG), a decoy peptide which prevents 
RANKL from binding to RANK. Upon binding of RANKL, activation of nuclear factor kappa B 
(NFκB) and mitogen-activated protein kinase (MAPK) signaling pathways increases 
transcription factors necessary for differentiation of osteoclasts. Osteoclast activation and 
differentiation leads to the resorption of bone. Estrogen signaling plays a large role in bone 
metabolism by regulating RANKL/OPG ratio, inhibiting osteoblast apoptosis, and increasing 
osteoclast apoptosis
67
.  
Epimedium has been reported to have beneficial effects on osteoporotic bone. Icariin is 
able to act similarly to estradiol and increase the expression of OPG/RANKL ratio as well as 
stimulate cell proliferation in UMR-106 cells. However, unlike estradiol, icariin did not induce 
ERE-dependent luciferase activity in UMR-106 cells via ERs, but did increase ERα 
phosphorylation at Ser118, a major site for ligand-independent activation of ER 
68
. Treatment of 
icariin in ovariectomized-induced osteoporotic mice resulted in upregulation of OPG and 
downregulation of RANKL gene expression
69
. Four components extracted from Epimedium, 
icariin, baohuoside-1, epimedin B and sagittatoside A had stimulatory effecst on cell 
proliferation in osteoblast-like UMR-106 cells.  These effects were abolished by co-treatment of 
cells with ICI 182,780. In a binding assay for ERα and ERβ, none of these compounds changed 
the binding of E2 to ERs. It was concluded that the stimulatory effect was likely due to 
interaction with ER, but not through its binding. ERα protein expression was suppressed in 
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UMR-106 cells with treatment of E2, baohuoside- I and epimedin B, and induced with treatment 
of icariin
70
.  
Epimedium and Estrogenicity 
It has already been established that Epimedium exhibits estrogenic activity by regulating 
bone cells. Epimedium and compounds isolated from epimedium have also been reported to have 
varying levels of estrogenicity in other cell types. Icaritin and desmethylicaritin, but not icariin, 
strongly stimulated proliferation of MCf-7/BUS cells. Increase in cells in S phase and significant 
increase in G2/M population similar to effects of estradiol. Treatment with icaritin or 
desmethylicaritin increased estrogen receptor-regulated progesterone receptor and PS2 mRNA 
levels. These effects were reversed by ICI 182, 780
71
. Icaritin and desmethylicaritin increased 
MCF-7 cell proliferation. Cell proliferation was antagonized by ICI 182, 780. Progestogen 
Receptor mRNA levels increased after treatment with icaritin and desmethylicaritin. These 
effects were not seen with icariin
72
. Icaritin inhibited the growth of breast cancer MCF-7 cell 
sand MDA-MB-453 cells
73
. 
Biosynthesis of estrogen from androgens in humans is catalyzed by aromatase CYP19A1. 
In humans, the major source of estrogen in premenopausal women comes from human ovarian 
granulosa cells. Treatment of KGN cells with a crude extract of Epimedium brevicornum was 
found to promote 17β-estradiol biosynthesis. These effects were also seen with treatment of 
KGN cells with icariin. Icariin treatment increased aromatase protein expression. The increase in 
17β-estradiol biosynthesis was abolished with aromatase inhibitor letrozole74. 
Epimedium and Breast Cancer 
Mice treated with icariin and icaritin via IP injection at 100 mg/kg three times a day for 
seven days after tumor inoculation treated had reduced tumor volume and contained splenocytes 
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with a significantly higher percent of IFN-у producing CD8+ T cells compared with control 
mice
75
. Athymic OVX female nude mice with MCF-7 breast cancer xenografts were fed high 
dose of epimedium extract (5000 mg/kg) for 16 weeks. Animals fed epimedium showed 
regression of tumors that were smaller compared to control animals after 16 weeks.ERα protein 
was reduced in tumor cells of animals fed 5000 mg/kg epimedium extract
76
. Icaritin at low 
concentrations stimulated growth of MCF-7 cells while higher concentrations suppressed MCF-7 
proliferation. Icaritin with estradiol suppressed estradiol-stimulated cell growth. The 
combination of estradiol and icaritin significantly reduced GREB1 mRNA, a critical hormone-
dependent regulator of breast cancer growth. Icaritin was found to competitively bind to AhR 
and acted as an AhR agonist. Icaritin reduced ERα protein levels in tumors of athymic OVX 
nude mice. Treatment with icaritin did not increase growth of MCF-7 breast tumor xenografts in 
athymic nude mice
77
.   
Icariin induces apoptosis through NFκB pathway 
Icariin has been shown to suppress NFκB through a non-classical pathway, leading to 
downstream decrease in anti-apoptotic factors. Icariin treatment induced apoptosis in both 
colorectal cancer cell line HCT116 and gallbladder cancer cell GB-SD. Icariin induced apoptosis 
in a dose dependent manner in human gallbladder carcinoma cell line via caspase-3 activity and 
decrease in antiapoptotic molecules Bcl-2, Bcl-xl and survivin through inhibition of NFκB. It 
also enhanced caspase-3 activity, induced G0-G1 phase arrest and suppressed the expression of 
Bcl-2, Bcl-xL and surviving proteins. Icariin inhibited constitutive NFκB as well as gemcitabine-
induced NFκB activity. Icariin also potentiated the effects of gemcitabine in vitro and in vivo78.  
Icariin inhibited cell proliferation in a dose dependent manner in colorectal cancer cells HCT116 
and HT29, although HCT116 cells were more sensitive than HT29. This effect was potentiated 
 
 
23 
 
 
when cells were treated with both icariin and radiation. When cells were pre-treated with icariin 
before exposure to radiation, NFκB was suppressed in comparison with cells that were exposed 
to radiation alone
79
. Cell viability of human non-small cell lung cancer A549 cells was inhibited 
by treatment of baohuoside I (isolated from Epimedium Koreanum), which resulted in apoptosis 
after 24 hours treatment. It was found that treatment with baohuoside I induced ROS production, 
which was diminished with ROS scavenger NAC incubation, reducing apoptosis levels
80
.  
High Fat Animal Model  
Epidemiological studies investigating the relationship between dietary fat and breast 
cancer are inconclusive. In rodent models, the relationship seems to be clearer, with a number of 
studies showing a link between high-fat diets and cancer growth. High fat diets were found to 
increase tumor growth in rodents when using syngeneic 4T1 mammary cancer cells, human 
MCF-7 mammary cancer cells, CT26 and HT-29 colon cancer cells. The Park group used the 
mammary mouse cell line 4T1 in the BALB/c mouse model fed a diet containing 60% 
kilocalories from total fat fed over 16 weeks. They showed that a 16-week feeding was sufficient 
to induce low-grade inflammation in this model, as noted by the increase in macrophage 
infiltration of the gonadal fat pad as well as an increase in serum cytokines (C5a, sICAM-1, IL-
16, M-CSF, TIMP-1, and TREM-1) in the mice fed high-fat diet
81
. There were only slight 
increases in body weight and gonadal adipose deposits between mice fed high-fat compared with 
mice fed control diet, while other adipose deposits were undetectable. Mice fed a high-fat diet 
implanted with 4T1 mammary tumors had reduced survival rate, increased solid tumor growth, 
and increased lung and liver metastasis compared with those fed a control diet. In athymic mice 
implanted with MCF-7 tumors, consumption of high-fat diet led to decreased numbers of splenic 
NK cells and altered regulation of cell cycle
82
. Similar results were observed using colon cancer 
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cell lines. In mice injected subcutaneously with CT26 colon cancer cells, mice fed a high-fat diet 
had significantly increased tumor growth and progression
83
. High-fat diet stimulated leuokocyte 
infiltration and angiogenesis in tumor tissues, seen by significant increases in serum VEGF and 
increased hemoglobin content in tumor tissues, Animals fed high-fat diet also had increased 
serum levels of growth factors and pro-inflammatory cytokines/chemokines. Mice injected with 
CT26 cells had significantly greater numbers of lung tumor nodules. In BALB/c nude mice with 
HT-29 cell xenograft, tumor tissues of mice fed high-fat diet had higher expression of PCNA and 
COX-2, which were confirmed with suppression of nuclear p21 levels and increased 
phosphorylation of ERK1 and mTOR proteins, suggesting activation of oncogenic pathways 
phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR and mitogen-activated protein kinase 
(MAPK)/ERK signaling cascades with the consumption of a high fat diet. 
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CHAPTER 3: LICORICE STUDY 
Abstract 
Licorice root, used for many centuries to treat various ailments, especially in Asian 
cultures, is a botanical supplement used by women to improve menopausal symptoms. Although 
the perception is that botanical supplement usage is safe, they contain phytoestrogens that are 
weakly estrogenic and are able to bind to estrogen receptors (ERs). This is especially dangerous 
in women who are at risk for developing breast cancer or have existing microtumors which have 
been undiagnosed.  This study aimed at determining the consequences of licorice root compound 
supplementation on breast cancer metastasis in a preclinical breast cancer model representative 
of late-stage breast cancer in women. We fed licorice root powder (LRP), licorice root extract 
(LRE), and isoliquiritigenin (ILQ) with a control (C) or high fat (HF) diet to ovariectomized 
Balb/c mice injected with 4T1 murine cells in the bone and measured the degree of metastasis to 
the lung. We demonstrated that licorice root consumption has the potential to modulate the 
degree of metastasis from bone to lung in an animal model fed a C diet. These effects were 
negated in a HF diet. In addition, licorice root compounds had no proliferative effects on uterine 
growth or terminal end bud enlargement in mammary gland. Although growth promoting effects 
on metastatic breast cancer were not observed with supplementation of licorice root and its 
constituents, more research to ascertain how licorice root compounds interact with other dietary 
components and in different tissues would help direct appropriate consumption of licorice root 
and its constituents in women with breast cancer. 
Introduction 
Breast cancer (BC) affects 12% of the female population and is the second leader of 
death in U.S women, with an estimated 60,290 new cases diagnosed in 2015
1
. However, survival 
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rates have improved drastically, with more than 2.8 million BC survivors living in the U.S. 
Complications from BC usually arise as a result of metastasis, with fewer treatments options and 
a focus on palliative care
2
. Micrometastasis, tiny undetectable tumors that are precursor to 
secondary tumors, were found in the bone at the time of diagnosis in approximately 30% of 
patients
3
. Metastasis to the bone can cause immense pain that decreases the quality of life in 
patients but is not life-threatening
4
. However, metastasis from the bone to lung lowers the life 
expectancy of the patient significantly
5
. Therefore, preventing the spread of tumor growth from 
bone to further tissues is ideal. Diet may play an important role in determining the progression of 
breast cancer. 
Menopause, which is marked by a reduction in ovarian function and a decline in the 
production of estrogens, is a natural process of aging in women. During menopause, symptoms 
such as weight gain, hot flashes, night sweats, mood changes, and diminished sexual function
6
 
may appear as a result.  Hormone Replacement Therapy (HRT) was commonly used to treat 
menopausal symptoms up until 2002, when results from the Women’s Health Initiative Study 
stated that hormone replacement therapy (HRT) in the forms of estrogen or estrogen with 
progesterone, were associated with a higher incidence of invasive breast cancer 
7
. Multiple 
epidemiological studies
8,9
 as well as randomized controlled trials
10,11
 have supported the original 
findings. Due to the increased risk to benefit ratio, use of HRT has decreased dramatically, and 
women have sought alternative treatments such as botanical supplements, which are thought to 
improve menopausal symptoms through their phytoestrogenic properties
12
.  
The phytoestrogens found in botanical supplements are structurally and behaviorally 
similar to estrogen, although their actions tend to be much weaker compared with estrogen. 
Estrogens play a crucial role in the female body by regulating menstruation, sexual development, 
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sexual reproduction, and metabolism, but can also contribute to the progression of breast cancer 
by binding to either of the estrogen receptors (ERs), ERα or ERβ. ERα is thought to carry out 
pro-oncogenic actions while ERβ plays an opposing role13,14. Botanicals have a higher affinity 
toward ERβ than ERα, but since the ERs share a large homology, possess the potential to turn on 
or off genes that regulate cancer growth
15
.  
Licorice root is a botanical supplement product that is marketed to relieve menopausal 
symptoms and is consumed by women. Licorice root has long been used for its sweetening and 
flavoring properties, but is also a botanical containing many bioactive components including 
triterpenoids, polyphenols, flavonoids and its effects on breast cancer are uncertain. There is 
evidence that licorice root has phytoestrogenic effects, with multiple components exhibiting 
estrogenic activity
16
. Isoliquiritigenin, a chalcone, is a major phytoestrogenic component found 
in licorice root which is in isomeric equilibrium with its flavonone liquiritigenin
17
. Both can bind 
to ERα and ERβ of various cell types and have displayed a biphasic effect on proliferation of 
breast cancer cells
18,19
. 
Studies regarding the role of high dietary fat consumption and breast cancer are 
inconsistent, but some suggest a positive correlation. Higher incidence of invasive breast cancer 
was found in women with higher intakes of total fat and saturated fat when compared with 
women with the lowest intakes of fat
20,21
. Women consuming greater amounts of saturated fat, 
monounsaturated fat, and total fat before breast cancer diagnosis were also reported to have a 
higher risk of death
22
. A diet high in dietary fat, along with the use of botanical supplements for 
menopausal symptoms, may have unintended consequences for those with or at high risk for 
developing breast cancer. The interactions exerted by a diet high in fat can complicate the 
situation.  
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In this study, we evaluated the potential efficacy of licorice root compounds in 
controlling the progression of metastatic breast cancer in the presence of a high fat diet. Our 
hypothesis is that licorice root compounds act as weak estrogens and will behave differently in 
hormone-sensitive tissues when compared with estrogen. We predicted that the supplementation 
of licorice root compounds will reduce metastasis to the lung when consumed with a control and 
high fat diet. This study investigated the safety of licorice root powder (LRP), licorice root 
extract (LRE), and isoliquiritigenin (ILQ) supplementation with and without high fat diet in a 
metastatic breast cancer mouse model. Outcomes measured were the influence of licorice root on 
blood serum metabolite levels, extent of metastatic growth to the lungs, hormone responsive 
tissues, and liver morphology. We found that LRP and ILQ, but not LRE reduced lung metastasis 
from the bone and that these effects were abolished when licorice root compounds were provided 
with a high fat diet. Additionally, none of the licorice root compounds induced growth in uterine 
or mammary gland tissues. 
Methodology 
Materials 
Heat-Inactivated Fetal Bovine Serum (HI-FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). Modified IMEM, Penicillin/Streptomycin, Fungizone and Trypsin-EDTA 
were purchased from Invitrogen (Carlsbad, CA). L-Glutamine was purchased from Sigma 
Chemical Co. (St Louis, MO). Matrigel
TM
 matrix was purchased from BD Biosciences (San Jose, 
CA). D-luciferin potassium salt was purchased from Regis Technologies (Morton Grove, IL). 
Isoflurane was purchased from Baxter Healthcare Corporation (Deerfield, IL). 
Cell Culture 
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Murine 4T1 cells with firefly luciferase gene were originally provided by Dr. David 
Piwnica-Worms from Washington University (St. Louis, MO). Murine 4T1 cells are a clonal 
tumor line derived from a spontaneous mammary tumor found in a BALB/cfC3H mouse
23
. 
Though these cells lack the expression of ER
24,25
, their growth can be stimulated by estradiol
26
.  
When injected into Balb/c mice, 4T1 cells spontaneously metastasize to other organs in a way 
that is similar to how breast cancer metastasis occurs in humans
27,28
. Cells are cultured in IMEM, 
supplemented with 10% HI-FBS, 100 unit/mL Penicillin, 100 µL/mL Streptomycin, 1% L-
Glutamine, and 0.1% Fungizone in a humidified incubator containing 5% CO2 at 37°C. Cells 
were harvested on passage 4 at 80% confluency. 
Animal Model 
Female Balb/C mice were obtained from Charles River Laboratories (Wilmington, MA). 
Mice were ovariectomized at 3 weeks old by the vendor and arrived at 5 weeks old. Animals 
were housed in single cages with standard light-dark cycle (12 hours light and 12 hours dark) and 
provided ad libitum access to food and water for the entire study, which lasted a total of 5 weeks. 
Mice were injected with 4T1 tumors in the tibia to mimic micrometastatic cancer in the bone 
after 2 weeks of feeding supplemented diet.  Mice are kept under general anesthesia with 
isoflurane/oxygen gas throughout the surgery. During the surgery, the mouse is placed facing up. 
The surface of the right tibia is shaved and an incision is made to expose the patellar tendon. A 
hole is created by inserting a 26-gauge needle into the joint surface of the tibia through the 
patellar tendon into the bone marrow cavity. A 25- μL Hamilton microsyringe with a 27-gauge 
needle is used to deliver 1,000 4T1 cells suspended in 2.5 µL Matrigel into the hole. The incision 
is sealed with tissue adhesive (3M Vetbond) and closed by surgical staple. Banamine (2.3 µg/g 
body weight) was administered subcutaneously after surgery and at 12 hours after surgery. All 
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animals were sacrificed 3 weeks after cell injection. All studies were conducted under animal 
experiment protocols approved by the Institutional Animal Care and Uses Committee (IACUC) 
at the University of Illinois at Urbana-Champaign. 
Diet Composition 
The study lasted a total of 5 weeks. After one week to allow for acclimation, mice from 
each study were randomized into two groups and were fed a standard AIN-93G control diet (C) 
containing16% kcal from fat (kcal/g) or modified AIN-93G high fat diet (HF) containing 45% 
kcal from fat in pellet forms until the end of the study. The AIN-93G semi-purified diet was 
chosen because it fulfills all the nutrient requirements of a mouse
29
. Diets were customized by 
Harlan Diets in order to match the percentage of kilocalories from macronutrients in the diets as 
closely as possible (Appendix A). Body weights and food intake were monitored weekly 
throughout the study. Food intake was calculated by subtracting the total amount of food left 
after one week from the total amount of food provided at the beginning of each week. 
Preparation of Licorice Compounds 
After 2 weeks from beginning of the study, C and HF diets were supplemented with 
licorice root powder (LRP), licorice root extract (LRE), isoliquiritigenin (ILQ) or no compound. 
These diets were supplied ad libitum to animals until sacrifice. Doses were selected based on 
predicted consumption levels by humans from dietary supplements
30
. Licorice root powder 
(Glycyrrhiza Glabra species) was prepared from the dried roots of licorice plant. Licorice root 
extract was then obtained from the methanolic fraction of LRP. LRP, (estimated to contain about 
10 mg of liquiritigenin and isoliquiritigenin per 1 g licorice root powder),
31
 was incorporated into 
C or HF diet at 500 g/kg of diet (the maximum volume that could be added without altering diet 
composition). LRE was incorporated into C or HF diet at 50 g/kg of diet. ILQ was incorporated 
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into C or HF diet at 5 g/kg of diet. LRP and LRE were provided by University of Mississippi. 
Isoliquiritigenin was purchased from Changsha Heir Biological-Tech Co, Ltd (China).  
Liver, Uterus, and Adipose Weights 
Liver, uterus, and adipose weights were recorded at sacrifice. Left liver lobe and adipose 
tissue was flash-frozen and stored at -80°F.  Right liver lobe, uterus, kidneys, spleen, and heart 
was preserved in formalin. Liver lobe was embedded into paraffin, sectioned onto slides, and 
stained with Hematoxylin and Eosin (H&E). Liver tissues were then graded using a scale of 0 to 
5 for the severity of lesions, where 0= none and 5=severe. The grading was evaluated in blind 
with no knowledge of treatment groups.  
Lung Histopathology  
The degree of metastasis was measured by quantification of lung tumor nodules. At 
sacrifice, lungs were excised, fixed in 10 % formalin for 24 hours and then stored in ethanol. 
Lungs were examined for surface tumor metastases by 3 individuals and counts were averaged. 
Any interaction effect between licorice root and high fat diet was determined using two-way 
ANOVA.  Lungs were then embedded in paraffin and sectioned into 5 µm slices for H&E 
staining. Sectioned lung tissues were scanned and observed using NanoZoomer Digital 
Pathology System (Hamamatsu Phototonics). Metastatic tumor area was measured as 
described
32
. Tumor area was presented as percentage of whole lung tissue area per section. All 
slides were measured in a blind fashion without the knowledge of treatment groups.  
Mammary Whole Mount 
During sacrifice, mammary gland tissue was excised, spread out on glass slide, and 
placed immediately into Carnoy’s fixative. Staining of whole mammary mounts was carried out 
per instructions provided by VitroView
TM
 Mammary Gland Whole Mount Stain Kit. Total 
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numbers of terminal end buds were counted by three individuals, independently and without 
knowledge of treatment groups.  
Bioluminescent Imaging (BLI) 
Animals were imaged using a custom made imaging system with dual microchannel plate 
ICCD camera twice weekly after cell injection for 3 weeks until end of study. 15 mg/mL 
luciferin was dissolved in PBS and 10 µL luciferin per gram of body weight administered into 
the animal via IP injection. After three minutes, the animal was anesthetized with 
isoflurane/oxygen gas and placed into the BLI imaging chamber (Stanford Photonics, Palo Alto, 
CA). A grey-scale image of the mouse was first recorded. Photon emission was then integrated 
for 3 minutes using imaging software Piper Control (Stanford Photonics, Palo Alto, CA) and 
visualized in pseudo-color. Images were processed to visualize location and spread of tumors 
using Piper Control Software, Image J (NIH, Bethesda, MD) and Photoshop Elements (Adobe, 
San Jose, CA) by merging grey-scale images and bioluminescent signals. Tumor area and 
integrated density on bone were analyzed using Image J. 
Blood Analysis 
Blood was drawn for serum metabolite analysis at sacrifice. A validated LC/MS/MS 
method with internal standard quantification (d3-daidzein and d4-genistein for LIQ and ILQ, 
respectively) was used to quantify total conjugated and aglycone forms of LIQ and ILQ (LODs 
0.2–6 nM depending on volume analyzed), without and with enzymatic hydrolysis, respectively 
(n = 8–10 mice).  
Statistical Analysis 
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An interaction effect was detected using two-way ANOVA (p=0.02459). Data was 
analyzed using one-way ANOVA to compare treatment effects of licorice botanicals within C or 
HF diets, followed by Hochberg procedure using statistical software R (version 3.1.3). 
Results 
Serum Concentrations of Liquiritigenin and Isoliquiritigenin 
Licorice root compounds were provided to animals for a total of five weeks (two before 
and three after cell injection.) On average, animals ingested approximately 2-3 g of feed per day 
and weighed an average of 23 g. This equated to about 5000 mg/kg BW LRP, 500 mg/kg BW 
LRE and 50 mg/kg BW ILQ per day. The studies were orchestrated to deliver quantities of 
whole botanical, botanical extract and isolated bioactive compound that contained comparable 
amounts of ILQ. Serum levels of isolquiritigenin primary metabolites, liquiritigenin and 
isoliquiritigenin, were found to be comparable in animals receiving LRP, LRE or ILQ (Table 
3.1). Because the timing of the last consumption of diets was not known with respect to sacrifice, 
the single-point estimates contain considerable uncertainty.  
Effects of Licorice Botanicals on Metastatic Breast Cancer  
There was no significant difference between metastasis observed in C and HF animals. In 
C animals supplemented with licorice root compounds, LRP and ILQ animals had a significant 
reduction in the number of tumors on the lung surface, while no significant reduction was found 
with LRE. (Figure 3.1) In HF animals supplemented with licorice root compounds, no changes 
were found in metastasis to the lung.  
Effects of Licorice Botanicals on Uterus Weight and Mammary Tissue 
In C animals supplemented with LRE, uterus weight was significantly increased. Uterus 
weight was not altered in all other animals receiving licorice root compounds (Figure 3.2) No 
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changes in mammary gland characteristics were seen in animals on HF diet when compared with 
those on C diet (Figure 3.3). Feeding of licorice root compounds did not impact the proliferation 
of terminal end buds in the mammary gland within C groups or HF groups (Figure 3.4).  
Effects of Licorice Botanicals on Body Weight and Energy Intake 
Weight gain in animals fed C and HF diet were comparable and did not significantly 
differ throughout the study.  Addition of licorice root compounds did not alter food intake of C 
or HF animals (Figures 3.5 and 3.6). Although food intake was higher in HF animals, average 
energy intake between animals fed C and HF diet were the same (Figures 3.7 and 3.8). HF 
feeding had no effect on gonadal adipose tissue deposits when compared with C diet. There were 
no changes observed in gonadal adipose tissue weights in animals fed licorice root compounds 
(Figure 3.9).  
Evaluation of Liver Morphology After Supplementation with Licorice Botanicals 
To assess any changes in organ morphology after licorice consumption, liver weight was 
collected at sacrifice. There were no differences in liver weight between animals fed C or HF 
diet. Liver weight was increased in mice consuming LRP (p<0.01) but was unaltered with 
supplementation with LRE and ILQ (Figure 3.10). Livers were graded for degree of diet-induced 
hepatocellular hypertrophy. Minimal to moderate hepatocellular hypertrophy was observed in 
livers of all animals fed LRP. Minimal to mild hepatocellular hypertrophy was observed in livers 
of animals fed LRE. Hepatocellular hypertrophy was not found in animals that did not receive 
licorice root compounds, except one. Results are summarized as averaged scores (Figure 3.11). 
Discussion  
The goal of this study was to determine the effects of licorice root supplementation on 
metastasis from bone to lung in a preclinical late-stage BC model within a C or HF diet. We 
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discovered that LRP and ILQ at the levels we provided reduced lung metastasis when 
supplemented with a C diet but had no effect on lung metastasis when supplemented with a HF 
diet. Licorice root botanicals did not increase metastatic growth in our animals. There were also 
no effects found in uterine tissue and mammary gland tissue, implying that licorice root 
compounds produced an estrogenic response different from that of estrogen. 
Previous literature has shown potential cancer-fighting benefits of licorice root in various 
forms, including the reduction of breast tumor growth
33,34
. Our study found that the consumption 
of LRP or ILQ in a C diet significantly reduced metastasis from bone to lung in our animal 
model. LRE had no significant effect on lung metastasis when compared to the control diet. 
Licorice root treatment has been shown to decrease factors associated with metastasis, such as 
VEGF and matrix metalloproteinases (MMPs) 2 and 9, as well as decrease the lung metastasis in 
mice inoculated with renal carcinoma cells and human breast cancer cells
35-38
. Our results with 
licorice root powder and isoliquritigenin are consistent with these studies. Though LRE did now 
show any significant effects, there was a trend toward reduction. The same consumption of LRP, 
LRE and ILQ in a HF diet had no effect on the extent of metastasis to the lung.   
Mammary gland proliferation was measured by counting the number of terminal end 
buds. Consumption of licorice root containing diets did not have any impact on the proliferation 
of terminal end buds. In addition, no impact was seen on the uterus weight, suggesting that LRP, 
LRE and ILQ did not have a proliferative effect on these reproductive tissues in animals. Feeding 
of licorice root compounds was determined not to have an effect on uterus weight or mammary 
gland and produced no changes in gene expression in these tissues in a similar study using C57 
mice
39
. Given what we know about the estrogenicity of licorice root compounds
19,40
, these results 
suggests that licorice root may behave similarly to a selective estrogen receptor modulator 
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(SERM), in that it can exhibit agonistic or antagonistic activities when binding to estrogen 
receptor depending on the target tissue. Another study supports this idea by illustrating that 
components found in licorice root extract in addition to isoliquiritigenin and liquiritigenin were 
potent estrogen agonists or partial estrogen antagonists
41
. However, licorice root contains 
multiple bioactive compounds in addition to isoliquiritigenin that could be acting through various 
mechanisms of action.  In order to confirm whether or not these physiological changes are solely 
due to binding of estrogen receptor, studies combining the administration of these compounds 
with an antiestrogen could be warranted. 
Blood serum metabolite levels showed that levels of liquiritigenin/isoliquiritigenin in the 
licorice root study were variable. Since diets were provided ad libitum, feeding times of animals 
were unregulated and the timing of last meal consumption was unknown. Thus, blood serum 
metabolite levels may not have been accurately reflected. Future studies should consider 
implementation of a feeding regimen providing specified amounts of diet at fixed times to avoid 
inconsistencies.   
Overall, body weight gain did not differ between C and HF groups. Compared with levels 
of fat used in high fat cancer models of other studies, the amount of fat in our C groups was 
higher than the amounts used in others control diets, while animals in our HF groups received 
lower amounts of fat.  In earlier studies, animal were fed control diets containing 10-13.5% kcal 
from fat and high fat diets containing 45-60% kcal from fat, with a feeding period of 16 weeks or 
longer
42-44
. We chose to use a diet containing 45% kcal from fat to parallel levels of fat attainable 
in humans (average consumption in U.S women is estimated to be ~33%)
45
, with a feeding 
period of 5 weeks. Balb/c mice are postulated to be highly obese-resistant due to increased 
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thermogenic capacity and efficient food intake regulation
46
. This model allowed us to isolate the 
effects of a high-fat diet without any confounding variables that might arise from obesity. 
Liver weights were significantly increased in the animals receiving LRP, and 
examination of liver tissue showed mild to moderate hepatocellular hypertrophy that is typical of 
liver adaptation to xenobiotics. The changes in the liver were not considered to be permanent, 
but long-term consumption of licorice in predisposed populations has been known to cause 
adverse effects such as edema, hypertension and hypokalemia
47
. These side effects have only 
been associated with glycyrrhizin, which is the major flavor component found in licorice root. 
LRE and ILQ, which do not contain glycyrrhizin, did not appear to have any significant effects at 
the levels consumed in our studies. While it was determined that consumption of 100 mg/day 
glycyrrhizin would not cause adverse effects in most adult humans
30
, it would be advisable in 
future long-term studies to limit or remove glycyrrhizin content from licorice components in 
order to obtain beneficial effects of licorice root without risk of toxicity from glycyrrhizin. 
Minimal changes were seen in kidney and spleens of animals receiving licorice root compounds 
compared with C or HF animals. Further examination of sectioned kidney and spleen tissues did 
not produce any evidence of structural abnormalities (Appendix A).  
In conclusion, licorice root did not contribute to the progression of late-stage metastatic 
breast cancer in our animal model. While licorice root had no effect on reproductive tissues, 
licorice root powder and isoliquiritigenin reduced the degree of metastasis within a control diet. 
The beneficial effects of licorice root on breast cancer metastasis were not seen with a high fat 
diet. Continued research of licorice root and the mechanisms behind these findings would help 
gain insight as to appropriate consumption of licorice root in women with breast cancer and 
indications for consumption with other components in the diet that may cause interactions. 
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Tables 
Table 3.1. Serum metabolites of licorice compounds. Blood levels of liquiritigenin (LIQ) and isoliquiritigenin 
(ILQ), as total and aglycones, in animals on control diets (C) or high fat diets (HF) containing licorice root powder 
(LRP), licorice root extract (LRE), or pure isoliquiritigenin (ILQ).  
 
Table 3.1 
 
Dose 
Group 
LIQ-Total 
(μM) 
LIQ-Aglycone 
(μM) 
% 
Aglycone 
LIQ/ILQ 
Ratio 
ILQ-Total 
(μM) 
ILQ-Aglycone 
(μM) 
% 
Aglycone 
 
C <LOD
a
 <LOD -- -- <LOD <LOD -- 
C-LRP 3.8 0.0034 0.1 8 0.46 0.0041 0.9 
C-LRE 1.9 0.0175 0.9 11 0.17 0.0014 0.8 
C-ILQ 0.037 <LOD -- 0.3 0.13 0.0083 6.4 
 
HF 0.014 <LOD -- -- <LOD <LOD -- 
HF-LRP 2.9 0.0054 0.2 11 0.27 0.0023 0.9 
HF-LRE 1.4 0.0036 0.3 16 0.09 0.0008 0.9 
HF-ILQ 0.055 0.0004 0.7 0.3 0.18 0.013 7.1 
a
<LOD=below level of detection 
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Figures 
Figures 3.1. Lung Tumor Metastasis. Surface tumors found on lungs of Balb/c mice after feeding licorice root 
powder (LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a Control (C) or High Fat (HF) diet. 
Results are expressed as means +/- SEM. N=10. p <0.05, N=10. Groups sharing a letter are not significantly 
different at the 5% level. 
Figure 3.1 
 
Figure 3.2. Uterus Weight Measurements. Changes in uterus weight after 4 weeks of feeding licorice root powder 
(LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a Control (C) or High Fat (HF) diet. Results are 
expressed as means +/- SEM. p<0.05, N=10. Groups sharing a letter are not significantly different at the 5% level.  
Figure 3.2 
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Figures 3.3 and 3.4. Mammary Gland Proliferation.  Representative images of mammary glands found in mice 
after 4 weeks of feeding licorice root powder (LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a 
Control (C) or High Fat (HF) diet (Figure 3.3). Terminal end bud numbers are expressed as means +/- SEM. 
p>0.05, n=10. Groups sharing a letter are not significantly different at the 5% level. (Figure 3.4) 
Figure 3.3 
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Figure 3.5, 3.6, 3.7, 3.8. Body Weight and Food Intake. Weekly food intake of Balb/c mice fed a Control (C, 
Figure 3.5) or High Fat (HF, Figure 3.6) diet and average energy intake (kcal) per day of Balb/c mice fed a C 
(Figure 3.7) or HF (Figure 3.8) diet. Results are reported as means +/- SEM. p>0.05, N=10. 
Figure 3.5     Figure 3.7 
  
Figure 3.6     Figure 3.8 
  
 
Figure 3.9. Gonadal Adipose Tissue Measurements. Changes in gonadal adipose tissue weight (g) after 4 weeks 
of feeding feeding licorice root powder (LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a Control 
(C) or High Fat (HF) diet. Results are expressed as means +/- SEM. p>0.05, N=10. Groups sharing a letter are not 
significantly different at the 5% level. 
Figure 3.9 
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Figure 3.10. Liver Weight Measurements. Changes in liver weight (g) after 4 weeks of feeding licorice root 
powder (LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a Control (C) or High Fat (HF) diet. 
Results are expressed as means +/- SEM. p<0.05, N=10. Groups sharing a letter are not significantly different at the 
5% level.  
Figure 3.10 
 
Figure 3.11. Hepatic Tissue Sectioning. Summary of graded hepatocellular hypertrophy (0=none to 5=severe) of 
livers from mice fed licorice root powder (LRP), licorice root extract (LRE), and isoliquiritigenin (ILQ) with a 
Control (C) or High Fat (HF) diet. Results are expressed as means +/- SEM. N=10 
Figure 3.11 
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CHAPTER 4: EPIMEDIUM STUDY 
Abstract 
Metastasis is a leading cause of death in breast-cancer (BC) related deaths. While the 
mechanisms that induce metastasis in breast cancer patients remain unclear, effects of diets have 
been implicated as a critical factor. Botanicals from the genus Epimedium have been marketed 
toward women for relief of menopausal symptoms, and have been shown to proffer multiple 
health benefits, including prohibitory growth effects in cancer. Epimedium has been postulated 
to have estrogenic properties, which can modulate transcription of genes that promote or repress 
tumor growth.  Studies have also suggested that higher consumption of dietary fat is related to 
breast cancer risk. The safety and efficacy of epimedium in promoting health among 
postmenopausal women who are at high risk of developing BC remains undetermined. Our group 
has characterized a preclinical model with metastatic 4T1 murine cells implanted into the tibial 
bone of Balb/C mice. This model is also responsive to changes in energy balance. Using this 
preclinical model, we provided amounts of epimedium powder (EP), epimedium extract (EE) 
and icariin (II) that would result in blood levels in mice similar to those found in humans. Our 
goal was to assess the potential health risk and/or benefit of epimedium using this model by 
examining the effect of epimedium on BC growth and metastasis in conjunction with a diet high 
in fat that is comparable to levels consumed in the general population. After 4 weeks of dietary 
supplementation, we found that EP, EE, and II did not stimulate metastatic growth within a 
control diet, while supplementation with EE (but not EP or II) reduced the amount of metastasis 
within a high fat diet.  In addition, dietary EP and EE, but not II, stimulated uterine and 
mammary gland tissue growth. Our results indicate that epimedium compounds induce 
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differential estrogenic responses in various tissues and may act as selective estrogen receptor 
modulators (SERMs).  
Introduction 
Breast cancer (BC) encompasses the largest percentage of cancers in women worldwide 
and is the most significant contributor to cancer related mortality
1
. Though breast cancer 
mortality rates have declined in the last ten years, there are still 40,000 American deaths due to 
breast cancer each year. Most of these deaths are due to cancer metastasis. This is the spread of 
cancer from the primary site to other areas of the body. It is estimated that 20-30% of all early-
stage breast cancers will become metastatic
2
. There is a strong likelihood of recurrence in distal 
tissues in women who have been successfully treated for a primary tumor as well. Bone 
metastasis occurs in 70% of patients with late-stage BC
3
, with micrometastasis in the bone 
marrow detected in 30.6% of women with invasive breast cancer before any diagnosis of 
metastatic breast cancer
4
.  Patients with metastasis are estimated to have a 5-year survival rate of 
26%
5
. There are currently no established standards of care for metastatic breast cancer. 
Therapeutic measures focus on disease control, palliative care for symptoms, and to maintaining 
quality of life
6
.   
The causes of tumor progression remain unclear, but dietary factors such as fat 
consumption may be a large contributor. Although the relationship between high-fat diets and 
breast cancer is debatable, multiple epidemiological studies implicate a role for high dietary fat 
consumption on breast cancer prognosis. Thiebaut et al. reported an 11% higher incidence of 
invasive breast cancer in women with median intake of 40.1% energy from total fat than women 
with median intake of 20.3% energy from total fat
7
. Sieri et al found a significantly greater risk 
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of developing breast cancer in women with a median saturated fat intake of 45% energy from 
saturated fat than with a median intake of 16.2% energy from saturated fat 
8
.  
Complementary and alternative medicine (CAM) has become increasingly prevalent in 
the U.S and has an estimated expenditure of $34.4 billion each year
9
. People with chronic disease 
are more likely to be CAM users than those without illness
10
. As high as 86% of breast cancer 
patients or survivors have been reported to use at least one form of CAM after diagnosis
11-13
. 
Breast cancer survivors who were CAM users and were at least one year beyond active medical 
treatment reported initiating or changing CAM activity due to their cancer diagnosis
14
. Wanchai 
reported that a large portion of patients are using biological-based practices such as herbs, 
vitamins and food
15
. Of particular concern are the use of botanical supplements, which contain 
phytoestrogens with varying levels of estrogenicity.  
Estrogen exposure can be a major contributor to breast cancer by stimulation of growth 
through estrogen signaling
16
. Estrogen signaling occurs through the binding of estrogen receptor 
(ER) by estrogen. There are predominantly two types of estrogen receptor, ERα and ERβ, which 
are found in many tissues of the body, like uterus, ovary, mammary gland, prostate, lung and 
brain. ERα is thought to carry out pro-oncogenic actions while ERβ plays an opposing role17,18. 
Phytoestrogens have similar structures to estrogen and tend to have a higher affinity toward ERβ 
than ERα 19. Due to the large homology of the ERs (~59%), phytoestrogens are still able to bind 
to ERα and therefore have the capability to stimulate cell growth.  
Plants of the genus Epimedium, also known as “barrenwort”, “horny goat weed” and 
“ying yang huo”, are marketed as a supplement for relief menopausal symptoms. It has a history 
for use in traditional Chinese medicine as an aphrodisiac and has also been used to treat a range 
of ailments such as impotence, hyperdiuresis, osteoporosis, menopause syndrome, rheumatic 
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arthritis, and hypertension
20
. Epimedium contains several flavonoids and lignans, many of which 
have been characterized to have estrogenic activities. The flavonoid Icariin is the major 
estrogenic bioactive present in many commonly used species of Epimedium, including 
Epimedium sagittatum, Epimedium brevicornum, and Epimedium koreanum. Studies have shown 
that epimedium possesses numerous benefits, including phytoestrogenic
21,22
,  osteoporotic, 
cardialogical
23,24
, and neuroprotective
25,26
 properties. However, there is a lack of conclusive 
evidence on the safety and efficacy of epimedium pertaining to breast cancer. Icaritin and 
desmethylcaritin, metabolites of icariin, have been shown to stimulate breast cancer cell 
proliferation
27,28
 while epimedium extract, icariin and icaritin have been shown to reduce the 
growth of breast tumors in a mouse model
29,30
. More studies are needed to determine the effects 
of epimedium and its relationship with breast cancer growth.  
Our goal was to determine the safety of epimedium consumption in menopausal women 
who are at risk for BC. Our hypothesis was that epimedium compounds are weak estrogens that 
will act similarly to licorice root. We predicted that supplementation of epimedium compounds 
will be able to reduce the number of metastatic lung nodules and that a high fat diet would negate 
or alter those effects. To test our hypothesis, we investigated the effects of epidemium powder 
(EP), epimedium extract (EE), and icariin (II) on metastasis of 4T1 murine breast cancer from 
bone to lung in a preclinical ovariectomized Balb/C model. Supplementation with EP, EE, and II 
had no effects on metastasis with a control diet, while supplementation with EE (but not EP or II) 
was found to reduce the amount of metastasis with a high fat diet. 
Methodology 
Materials 
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Heat-Inactivated Fetal Bovine Serum (HI-FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). Modified IMEM, Penicillin/Streptomycin, Fungizone and Trypsin-EDTA 
were purchased from Invitrogen (Carlsbad, CA). L-Glutamine was purchased from Sigma 
Chemical Co. (St Louis, MO). Matrigel
TM
 matrix was purchased from BD Biosciences (San Jose, 
CA). D-luciferin potassium salt was purchased from Regis Technologies (Morton Grove, IL). 
Isoflurane was purchased from Baxter Healthcare Corporation (Deerfield, IL). 
Cell Culture 
Murine 4T1 cells with firefly luciferase gene were originally provided by Dr. David 
Piwnica-Worms from Washington University (St. Louis, MO). Murine 4T1 cells are a clonal 
tumor line derived from a spontaneous mammary tumor found in a BALB/cfC3H mouse
31
. 
Though these cells lack the expression of ER
32,33
, their growth can be stimulated by estradiol
34
.  
When injected into Balb/c mice, 4T1 cells spontaneously metastasize to other organs in a way 
that is similar to how breast cancer metastasis occurs in humans
35,36
. Cells are cultured in IMEM, 
supplemented with 10% HI-FBS, 100 unit/mL Penicillin, 100 µL/mL Streptomycin, 1% L-
Glutamine, and 0.1% Fungizone in a humidified incubator containing 5% CO2 at 37°C. Cells 
were harvested on passage 4 at 80% confluency. 
Animal Model 
Female Balb/C mice were obtained from Charles River Laboratories (Wilmington, MA). 
Mice were ovariectomized at 3 weeks old by the vendor and arrived at 5 weeks old. Animals 
were housed in single cages with standard light-dark cycle (12 hours light and 12 hours dark) and 
provided ad libitum access to food and water. Mice were injected with 4T1 tumors in the tibia to 
mimic micrometastatic cancer in the bone after 2 weeks of feeding supplemented diet (after 16 
weeks from the beginning of the study.)  Mice are kept under general anesthesia with 
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isoflurane/oxygen gas throughout the surgery. During the surgery, the mouse is placed facing up. 
The surface of the right tibia is shaved and an incision is made to expose the patellar tendon. A 
hole is created by inserting a 26-gauge needle into the joint surface of the tibia through the 
patellar tendon into the bone marrow cavity. A 25- μL Hamilton microsyringe with a 27-gauge 
needle is used to deliver 1000 4T1 cells suspended in 2.5 µL Matrigel into the hole. The incision 
is sealed with tissue adhesive (3M Vetbond) and closed by surgical staple. Banamine (2.3 µg/g 
body weight) was administered subcutaneously after surgery and at 12 hours after surgery. All 
animals were sacrificed 3 weeks after cell injection. All studies were conducted under animal 
experiment protocols approved by the Institutional Animal Care and Uses Committee (IACUC) 
at the University of Illinois at Urbana-Champaign. 
Diet Composition 
The study lasted a total of 19 weeks. After one week to allow for acclimation, mice from 
each study were randomized into two groups and were fed a standard AIN-93G control diet (C) 
containing16% kcal from fat (kcal/g) or modified AIN-93G high fat diet (HF) containing 45% 
kcal from fat in pellet forms until the end of the study. The AIN-93G semi-purified diet was 
chosen because it fulfills all the nutrient requirements of a mouse
37
. Diets were customized by 
Harlan Diets in order to match the percentage of macronutrients in the diets as closely as possible 
(Appendix A). Body weights and food intake were monitored weekly throughout the study.  
Preparation of Epimedium Compounds 
Dietary treatments with botanicals were provided for a total of 4 weeks. After 14 weeks 
from beginning of the study, C and HF diets were supplemented with epimedium powder (EP), 
epimedium extract (EE), icariin (II) or no compound, which were supplied ad libitum to animals 
until sacrifice. Epimedium powder was prepared from the dried leaves of epimedium plant. 
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Epimedium extract (estimated to contain 10% of the icariin from epimedium powder) was then 
obtained from the methanolic fraction of epimedium powder. EP was incorporated into C or HF 
diet at 50,000 mg/kg of diet (the maximum volume that could be added without altering diet 
composition). EE was incorporated into C or HF diet at 5,000 mg/kg of diet. Icariin was 
incorporated into C or HF diet at 500 mg/kg of diet. EP and EE were provided by University of 
Mississippi. II was purchased from Changsha Heir Biological-Tech Co, Ltd (China). 
Liver, Uterus, and Adipose Weights 
Liver, uterus, and adipose weights were recorded at sacrifice. Left liver lobe and adipose 
tissue was flash-frozen and stored at -80°F.  Right liver lobe, uterus, kidneys, spleen, and heart 
was preserved in formalin.  
Lung Histopathology  
The degree of metastasis was measured by quantification of lung tumor nodules. At 
sacrifice, lungs were excised, fixed in 10 % formalin for 24 hours and then stored in ethanol. 
Lungs were examined for surface tumor metastases by 3 individuals and counts were averaged.  
Mammary Whole Mount 
During sacrifice, mammary gland tissue was excised, spread out on glass slide, and 
placed immediately into Carnoy’s fixative. Staining of whole mammary mounts was carried out 
per instructions provided by VitroView
TM
 Mammary Gland Whole Mount Stain Kit. Total 
numbers of terminal end buds were counted by three individuals, independently and without 
knowledge of treatment groups.  
Bioluminescent Imaging (BLI) 
Animals were imaged using a custom made imaging system with dual microchannel plate 
ICCD camera twice weekly after cell injection for 3 weeks until end of study. 15 mg/mL 
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luciferin was dissolved in PBS and 10 µL luciferin per gram of body weight administered into 
the animal via IP injection. After three minutes, the animal was anesthetized with 
isoflurane/oxygen gas and placed into the BLI imaging chamber (Stanford Photonics, Palo Alto, 
CA). A grey-scale image of the mouse was first recorded. Photon emission was then integrated 
for 3 minutes using imaging software Piper Control (Stanford Photonics, Palo Alto, CA) and 
visualized in pseudo-color. Images were processed to visualize location and spread of tumors 
using Piper Control Software, Image J (NIH, Bethesda, MD) and Photoshop Elements (Adobe, 
San Jose, CA) by merging grey-scale images and bioluminescent signals. Tumor area and 
integrated density on bone were analyzed using Image J. 
Blood Analysis 
Blood was drawn to conduct analyses of epimedium metabolites at sacrifice. A validated 
LC/MS/MS method with internal standard quantification (d3-daidzein and d4-genistein) was 
used to quantify total II (icariin), ICT (icaritin) and DICT (desmethylicaritin), with n = 16–18 
mice.  
Statistics 
Data was analyzed using two-way ANOVA to compare treatment effects of epimedium 
botanicals within C and HF diets, using R (version 3.1.3). Tumor nodules counts were analyzed 
using one-way Poisson regression model adjusted for overdispersion. 
Results 
Blood Serum Metabolites 
Serum levels of icariin primary metabolites, icaritin and desmethylicaritin were found to 
be similar in animals consuming EP, EE or II with C or HF diets (Table 4.1). Levels of ICT and 
DICT appear to be twice as high in animals fed EE compared with EP diet. Because the timing 
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of the last consumption of diets was not known with respect to sacrifice, the single-point 
estimates contain considerable uncertainty.  
Evaluation of Hormone Responsive Tissues 
There were no high fat effects detected on uterine weight between animals fed C or HF 
diet. Supplementation with EP and EE, but not II, in both C and HF diets resulted in heavier 
uterine weights in mice (Figure 4.1). Epimedium compounds also produced changes visible to 
the naked eye of mammary glands in mice. Thicker uterine lining and extensive branching was 
observed (Figure 4.2). Increased numbers of tumor end buds were found in mammary glands of 
animals fed EP and EE, but not in II (Figure 4.3).  
Evaluation of Lung Metastasis 
No differences in lung metastasis were found in mice supplemented with epimedium 
compounds when compared with those consuming C diet. Mice supplemented with EP in a HF 
diet showed significant reductions in the number of surface tumors found on the lung using one-
way Poisson regression to adjust for overdispersion (Figure 4.4).  
High Fat Animal Model and Weight Gain 
Body weights did not differ between animals in the C or HF diet groups. 
Supplementation with epimedium compounds did not have an effect on weight gain in C or HF 
groups (Figures 4.5 and 4.6). Average energy intake was comparable across all groups 
throughout the study (Figure 4.7 and 4.8). Mice supplemented with epimedium extract (EE) and 
fed either a C or HF diet had lower gonadal adipose tissue weights (Figure 4.9). Supplementation 
with epimedium powder (EP) or icariin (II) did not produce any weight changes in mesenteric, 
peri-renal or brown adipose tissues. (Appendix B).  
Evaluation of Organ Weights  
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There was no impact on liver weights of mice supplemented with epimedium compounds 
in either C or HF mice (Appendix B). There was an increase in kidney weights of mice 
supplemented with EP (p<0.05), but not EE or II (Figure 4.10). Spleen weights were 
significantly decreased in kidney weights of mice supplemented with II, but not EP or EE 
(Figure 4.11). 
Discussion  
Epimedium and its constituents have been shown to alter cell cycle differentiation in 
tumor cells and in some cases to stimulate or inhibit cell proliferation, but it is still unclear 
whether epimedium has stimulatory or inhibitory effects on in vivo cancer growth. We found that 
supplementation of epimedium compounds with C diet produced no changes in tumor metastasis 
to the lung when compared to C. Epimedium compounds supplemented with HF diet showed a 
trend in decreasing lung tumors, but due to high variability within the HF group, only EP was 
statistically significant.  Blood serum samples showed that icaritin (ICT) and desmethylicaritin 
(DICT), metabolites of icariin, were present in very low amounts at pM/μL levels, while levels 
of icariin were almost nonexistent. This shows that the majority of icariin was metabolized to its 
metabolites, although the levels of icariin delivered to the animal were most likely low to begin 
with.  
To our knowledge, this study is the first to look at the effects of icariin supplementation 
on tumor metastasis of breast cancer in a live animal. Animal studies have mainly looked at the 
anti-cancer potentials of icaritin, which has been shown to suppress growth of cancer cells in a 
dose-dependent and time-dependent manner, as well as decrease tumor growth in 4T1 breast 
tumors
38
. Growth of human renal carcinoma xenografts in immunodeficient mice were also 
decreased with icaritin treatment
39
. Many groups have found that treatment with icariin alone and 
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in combination with other treatments sensitizes cancer cells and promotes cell death; however, 
these have not been translated into animal studies. Icariin in combination with gemcitabine, 5-
fluorouracil, and radiation therapy has led to decreased cell proliferation and increased apoptosis 
in colorectal cancer cells through the suppression of NF-KB
40-42
.  Other bioactive components 
found in epimedium besides icariin have shown potential for slowing metastasis. Bauhuoside I 
was found to downregulate CXCR4, a key mediator of tumor metastasis, in cervical and breast 
cancer cells
43
. Icariside II decreased cell migration, invasion and epithelial-mesenchymal 
transition of lung cancer cells, as well as decreased the lung metastasis of nude mice
44
. It is likely 
that the reductive effects of EP are due to the combined action of several bioactive components 
which are not present in EE or II.  
 We found effects from epimedium on two estrogen responsive tissues. Epimedium had a 
similar growth-promoting effect in both uterine tissue and mammary gland tissue. These actions 
corresponded with responses in the presence of estradiol. Because our animals were 
ovariectomized and were not producing any endogenous estrogens, all changes were attributed to 
treatment effects. Epimedium and icariin have exhibited differential effects at low and high 
concentrations. Administration of epimedium flavonoids were reported to increase uterine 
weight at levels of 500 mg/kg of feed and had no effect on uterine weight at higher levels (1500 
and 5000 mg/kg feed)
29
. Icariin also increased uterine weight at levels of 10 and 20 mg/kg BW 
per day
22
, while another group found no changes to uterine weight with icariin administration at 
110 mg/kg BW
45
. The levels of EP and EE provided in our study at 50,000 and 5,000 mg/kg of 
feed was much higher than those used in previous studies.  
The current study included dietary fat as an independent variable due to the higher 
consumptions of fat in the average American woman. While the animals in our high fat groups 
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did not gain a significant amount of weight compared with the control groups, a prior study using 
the Balb/c athymic nude mouse strain led to altered physiology such as a decrease in splenic NK 
cells, changes in tumor gene expression involved with cell cycle regulation, overexpression of 
tumor mRNA glycolytic enzymes, and higher vascular endothelial growth receptor 2 (VEGFR-2) 
in tumor despite a lack of change in body weight
46
. Animals from other studies had significantly 
greater body weights when fed a high fat diet compared with control diet, which successfully 
induced an inflammatory state that resulted in increased tumor growth and/or metastasis. These 
studies used control diets containing 10-13.5% kcal from fat and high fat diets containing 45-
60% kcal from fat, with a feeding period of 16 weeks or longer
47,48
. Our studies used a control 
diet containing 18% kcal from fat and a high fat diet containing 45% kcal from fat to closer 
match a level of fat attainable in humans (average consumption is estimated to be ~33% in U.S 
women)
49
, with a feeding period of 16 weeks before cell injection. The Balb/c mouse strain has 
increased thermogenic capacity and improved fat catabolism, thus making them very effective at 
regulating food intake
50
. Because Balb/c mouse is known to be highly obese-resistant, we are 
able to investigate a high-fat model without any confounding variables that might arise with 
obesity.  
Herba epimidii has been shown to produce adverse effects at higher levels when 
consumed for long periods of time, but most adverse effects have been reported in a specific 
subset of patients or animals
51
. Because our animals were relatively healthy and received 
epimedium supplementation for only four weeks, it was unlikely that there would be any toxicity 
or adverse incidences. In this study, we did not observe any toxic effects from Herba Epimidii. 
Animals maintained steady body weight growth rates throughout the study, and no changes in 
liver weight were seen in animals supplemented with epimedium compounds. Animals receiving 
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EP had increases in kidney weight that were significant. Spleen weights in animals supplemented 
with II were significantly lower. Although these parameters were significant, these changes do 
not necessarily indicate toxicity.  
Conclusion 
The aim of this study was to examine the safety of consuming epimedium compounds as 
a supplement in a population at risk for developing breast cancer and to assess the impact of 
consuming botanicals on breast cancer metastasis. We accomplished this by supplementing EP, 
EE, and II with a C or HF diet in a metastatic mouse model that follows a metastatic pattern from 
the bone to lung.  We found that EP and EE produced significant changes in the uterus and 
mammary gland indicative of an estrogenic response. Epimedium compounds had no effect on 
metastasis to the lung when compared with C. EP significantly reduced the extent of metastasis 
to the lung when compared with HF, while EE and II animals tended to have lower amounts of 
metastasis but were not significant. Overall, epimedium compounds had no proliferative effects 
on breast cancer metastasis but induced uterus and mammary gland growth. Our results suggest 
that the consumption of epimedium is safe in menopausal women who are at risk of developing 
breast cancer. However, further research is required to confirm these findings and determine safe 
levels of consumption in humans.  
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Tables 
Table 4.1. Serum metabolites of epimedium compounds. Blood levels of total icariin (II), desmethylicaritin 
(DICT), and icaritin (ICT), in animals on control diets (C) or high fat diets (HF) containing epimedium powder (EP), 
epimedium extract (EE), or pure icariin (II).  
Table 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dose 
Group 
II-Total 
(pM/μL) 
DICT-Total 
(pM/μL) 
ICT-Total  
(pM/μL) 
 
C <LOD
a
 <LOD <LOD 
C-EP 0.0007 0.1300 0.0782 
C-EE <LOD 0.2367 0.1865 
C-II 0.0010 0.1280 0.0880 
 
HF <LOD <LOD <LOD 
HF-EP 0.0004 0.0700 0.0609 
HF-EE 0.0004 0.1282 0.1305 
HF-II <LOD 0.0030 0.0159 
a
<LOD=below level of detection  
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Figures 
Figure 4.1. Uterus Weight Measurements. Changes in uterus weight after 4 weeks of feeding epimedium powder 
(EP), epimedium extract (EE), and icariin (II) with a Control (C) or High Fat (HF) diet. Results are expressed as 
means +/- SEM. **p<0.01, ***p<0.001, N=18. 
Figure 4.1 
 
Figures 4.2 and 4.3. Mammary Gland Proliferation.  Representative images of mammary glands found in mice 
after 4 weeks of feeding epimedium powder (EP), epimedium extract (EE), and icariin (II) with a Control (C) or 
High Fat (HF) diet (Figure 4.2). Terminal end bud numbers are expressed as means +/- SEM, ***p<0.001,N=18. 
(Figure 4.3). 
Figure 4.2 
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Figure 4.3 
 
 
 
Figure 4.4. Lung Tumor Characterization. Surface tumors found on lungs of Balb/c mice after feeding 
epimedium powder (EP), epimedium extract (EE), and icariin (II) with a Control (C) or High Fat (HF) diet. Results 
are expressed as means +/- SEM. One-way Poisson regression model adjusted for overdispersion. *p<0.05, N=18. 
Figure 4.4 
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Figures 4.5, 4.6, 4.7, and 4.8. Body Weight and Food Intake. Weekly food intake of Balb/c mice fed a Control, C 
(Figure 4.5) or High Fat, HF (Figure 4.6) diet and average energy intake (kcal) per day of Balb/c mice fed a 
Control, C (Figure 4.7) or High Fat, HF (Figure 4.8) diet. Results are reported as means +/- SEM. p>0.05, N=18. 
Figure 4.5 
Figure 4.6  
Figure 4.7  
Figure 4.8  
Figure 5.55  
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Figure 4.9. Gonadal Adipose Tissue Measurements. Changes in gonadal adipose tissue weight (g) after 4 weeks 
of feeding epimedium powder (EP), epimedium extract (EE), and icariin (II) with a Control (C) or High Fat (HF) 
diet. Results are expressed as means +/- SEM. *p<0.05, N=18. 
Figure 4.9 
  
Figure 4.10. Kidney Weight Measurements. Changes in kidney weight (mg) after 4 weeks of feeding epimedium 
powder (EP), epimedium extract (EE), and icariin (II) with a Control (C) or High Fat (HF) diet. Results are 
expressed as means +/- SEM. **p<0.01, N=18. 
Figure 4.10 
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Figure 4.11. Spleen Weight Measurements. Changes in spleen weight (mg) after 4 weeks of feeding epimedium 
powder (EP), epimedium extract (EE), and icariin (II) with a Control (C) or High Fat (HF) diet. Results are 
expressed as means +/- SEM. *p<0.05, N=18. 
Figure 4.11 
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CHAPTER 5: SUMMARY & FUTURE DIRECTIONS 
Licorice root and epimedium supplements are marketed toward women as an alternative 
to HRT for menopausal symptom relief. Although some studies have reported them to be 
effective or beneficial for menopausal symptoms, they may pose a risk due to their 
phytoestrogenic properties. As evidenced by the results from these studies, licorice root and 
epimedium are both botanical supplements which are perceived to be safe and beneficial but 
have very different in vivo effects. We investigated the effect of licorice root and epimedium 
supplementation on late-stage breast cancer metastasis and demonstrated that licorice root 
consumption has the potential to modulate the degree of metastasis from bone to lung in an 
animal model while having no effect on the uterus or mammary gland. These effects were only 
seen with a control diet consisting of 18% kcal from fat and not with a high-fat diet consisting of 
45% kcal from fat. In contrast, epimedium compounds appeared to have no effect on metastasis 
with a control diet. A decrease in metastasis was observed in animals supplemented with 
epimedium powder in a high fat diet, although this interpretation may be disputable due to the 
high degree of variability within groups. Epimedium powder and epimedium extract stimulated 
structures of the uterus and mammary gland, indicating a strong estrogenic effect.  
The consumption of botanical phytoestrogenic supplements are viewed to provide the 
same type of benefits and provide the same type of relief for menopausal symptoms. However, 
these studies demonstrated that depending on the type of botanical, the phytoestrogenic effects 
can vary widely and are tissue-specific. Though licorice root and epimedium showed 
phytoestrogenic effects in vivo, the effects were seen in different tissues. The diversity of 
compounds found in botanical compounds and extracts likely contribute to the differential 
phytoestrogenic activities. Continued research of other botanicals, as well as licorice root and 
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epimedium, would help characterize their activities and aid in outlining appropriate usage of 
various botanicals. 
Our current animal is advantageous because it follows a similar pattern of metastasis in 
humans while maintaining an intact immune system. However, the increased metabolism and 
obese-resistant phenotype of this model is not as favorable when conducting studies of energy-
balance. As seen in our studies as well as others, the responses to a high fat diet in Balb/c mice 
are dissimilar compared with the responses that would be seen in humans.  High fat diets are 
often high in other macronutrients as well, whereas our high fat diet was formulated to match the 
control diet as closely as possible in all parameters except fat. In addition, the types of fat 
incorporated into the AIN-93G diet are not representative of a human diet. Combining the 
metastatic model used in this study along with the administration of a Western diet may better 
reflect human outcomes.  
Though our studies were designed to deliver similar amounts of isoliquiritigenin and 
epimedium, these were broad estimates. Providing animals with diets ad libitum added another 
element of uncertainty. Knowing that these compounds have differing effects at low and high 
concentrations, determining effects at different doses is vital. Supplying botanicals of a single 
form in precise amounts of increasing increments ranging from 25-5000 mg/kg BW would help 
ascertain any dose-dependent relationships.  
Of interest are the positive effects of epimedium on bone. We have already established 
that epimedium has a stimulatory effect on uterus and mammary gland. Many studies have also 
shown the beneficial effects of epimedium on osteoporosis, which may have implications for 
growth and metastasis of tumors in the bone. Bone metastasis causes severe pain and increases 
risk for fractures. Investigation of epimedium supplementation on bone morphology and fracture 
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risk associated with bone tumor growth would provide insight into the safety of epimedium use 
on tumors in the bone.  
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Appendix A 
Study Design of Licorice Root Study. 
 
Diet Composition. Composition of Control (C) and High Fat (HF) Diets 
 Control AIN-93G (Low-fat) Modified AIN-93G (High Fat) 
 Gram % Kcal % Gram % Kcal % 
Casein 200  240  
L-Cystine 3  3.6  
Corn Starch 397.486  124.683  
Maltodextrin 132  158  
Sucrose 100  119  
Lard -  155  
Soybean Oil 70  83  
Cellulose 50  59.7  
Mineral Mix 35  42  
Vitamin Mix 10  12  
Choline Bitartrate 2.5  3  
TBHG 0.014  0.017  
Total 1000  974.4  
Protein 17.7 18.8 21.2 18.4 
Carbohydrate 60.1 63.9 40.2 34.8 
Fat 7.2 17.2 24.0 46.8 
 
 
5 weeks 
Control (16% kcal from fat) or 
High Fat (45% kcal from fat) Diet 
+ 
Supplementation with LRP, LRE, 
ILQ or no compound 
3 weeks 
Tibial Injection  
S
a
c
rific
e
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Toxicological Evaluation. Summary of Evaluation of Liver, Gallbladder, Kidneys, Spleen and Heart from Histological Slides Stained with H&E in animals fed 
LRP, LRE and ILQ in a C or HF diet.   
 
 
 
83 
 
 
 
 
 
84 
 
 
Lung Tumors Histology. Representative Images of Histological Lung Sections Stained with H&E at 10x magnification in lungs of animals supplemented with 
LRP, LRE and ILQ in a C or HF diet.  
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Bioluminescence Imaging (BLI). Representative Images of Tibial Tumors imaged with BLI on Day 8 after Injection in animals supplemented with LRP, LRE 
and ILQ in a C or HF diet. 
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Appendix B 
Study Design of Epimedium Study. 
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Diet Composition. Composition of Control (C) and High Fat (HF) Diets 
 Control AIN-93G (Low-fat) Modified AIN-93G (High Fat) 
 Gram % Kcal % Gram % Kcal % 
Casein 200  240  
L-Cystine 3  3.6  
Corn Starch 397.486  124.683  
Maltodextrin 132  158  
Sucrose 100  119  
Lard -  155  
Soybean Oil 70  83  
Cellulose 50  59.7  
Mineral Mix 35  42  
Vitamin Mix 10  12  
Choline Bitartrate 2.5  3  
TBHG 0.014  0.017  
Total 1000  974.4  
Protein 17.7 18.8 21.2 18.4 
Carbohydrate 60.1 63.9 40.2 34.8 
Fat 7.2 17.2 24.0 46.8 
 
Levels of Icariin and Derivatives in Feed. Levels of Icariin (II), icariside I (ICARI), icariside II (ICARII), 
desmethylicaritin (DICT), and icaritin (ICT) detected in pelleted feed.  
 
 
FEED 
PERCENTAGE 
IN FEED 
SAMPLE 
TOTAL 
II 
(MG/G) 
TOTAL 
ICARI 
(MG/G) 
TOTAL 
ICARII 
(MG/G) 
TOTAL 
DICT 
(MG/G) 
TOTAL 
ICT 
(MG/G) 
 - CONTROL LOD LOD LOD LOD LOD 
5% C-EP 0.27 0.007 0.034 LOD 0.009 
0.50% C-EE 0.22 0.006 0.030 LOD 0.007 
0.05% C-II 0.41 0.005 0.001 LOD LOD 
 - HIGH FAT LOD LOD LOD LOD LOD 
5% HF-EP 0.20 0.005 0.027 LOD 0.006 
0.50% HF-EE 0.20 0.005 0.025 LOD 0.006 
0.05% HF-II 0.04 0.0005 LOD LOD LOD 
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Adipose Tissue Weights. Mesenteric Adipose Tissue (MAT), Peri-renal Adipose Tissue (PAT), and Brown 
Adipose Tissue (BAT) Weights after Supplementation with EP, EE, and II in a C or HF diet.  
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Bioluminescence Imaging (BLI). Representative Images of Tibial Tumors imaged with BLI on Day 8 after Injection in animals supplemented with EP, EE and 
II in a C or HF diet. 
 
 
